Prevention of chemotherapy-induced nausea and vomiting and the role of neurokinin 1 inhibitors: from guidelines to clinical practice in solid tumors

Anti-Cancer Drugs

Volumn 24, Issue 2, 2013, Pages 99-111

  Di Maio, Massimo ^a   Bria, Emilio ^b   Banna, Giuseppe L ^c   Puglisi, Fabio ^d   Garassino, Marina C ^e   Lorusso, Domenica ^e   Perrone, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c CANNIZZARO HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL OF UDINE   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

antiemetics; aprepitant; breast cancer; chemotherapy induced nausea and vomiting; colorectal cancer; guidelines; lung cancer; neurokinin 1 inhibition; ovarian cancer

Indexed keywords

APREPITANT; ASTEMIZOLE; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CASOPITANT; CHLORMETHINE; CISAPRIDE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANISETRON; IRINOTECAN; METHOTREXATE; ONDANSETRON; OXALIPLATIN; PALONOSETRON; PIMOZIDE; PREDNISOLONE; PREDNISONE; TERFENADINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL PRACTICE; COLORECTAL CANCER; CORTICOSTEROID THERAPY; COST BENEFIT ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MESOTHELIOMA; NEUROPHARMACOLOGY; OVARY CANCER; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; STOMACH CANCER; TREATMENT RESPONSE;

EID: 85027922274     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328359d7ba     Document Type: Review

References (70)

1. Warr DG. Chemotherapy- And cancer-related nausea and vomiting. Curr Oncol 2008; 15 (SUPPL1):S4-S9
2. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15:103-109
3. Hesketh PJ. Chemotherapy-Induced nausea and vomiting. N Engl J Med 2008; 358:2482-2494
4. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999; 17:2971-2994
5. Goedhals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: A double-blind, placebo-controlled, comparative study. Ann Oncol 1998; 9:661-666
6. Pisters KM, Kris MG. Treatment-related nausea and vomiting. In: Berger A, Portenoy RK, Weissman DE, editors. Principles and practice of supportive oncology. Philadelphia, PA: Lippincott-Raven; 1998. pp. 165-177
7. Hursti TJ, Avall-Lundqvist E, Börjeson S, Fredrikson M, Fü rst CJ, Steineck G, Peterson C. Impact of tumour burden on chemotherapy-Induced nausea and vomiting. Br J Cancer 1996; 74:1114-1119
8. Roscoe JA, Morrow GR, Colagiuri B, Heckler CE, Pudlo BD, Colman L, et al. Insight in the prediction of chemotherapy-Induced nausea. Support Care Cancer 2010; 18:869-876
9. Wilder-Smith OH, Borgeat A, Chappuis P, Fathi M, Forni M. Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 1993; 72:2239-2241
10. Diemunsch P, Gré lot L. Potential of substance P antagonists as antiemetics. Drugs 2000; 60:533-546
11. Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 2002; 63 (s11):18-24
12. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, et al. On the receiving end - Patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19:203-208
13. Griffin AM, Butow PN, Coates AS, Childs AM, Ellis PM, Dunn SM, et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996; 7:189-195
14. De Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, et al. Patient perceptions of the side-effects of chemotherapy: The influence of 5-HT3 antagonists. Br J Cancer 1997; 76: 1055-1061
15. Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins S, et al. Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract 1999; 7:59-65
16. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of postchemotherapy nausea and vomiting in patients with cancer: Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1997; 15:116-123
17. Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life: The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 1997; 5:307-313
18. Rusthoven JJ, Osoba D, Butts CA, Yelle L, Findlay H, Grenville A. The impact of postchemotherapy nausea and vomiting on quality of life after moderately emetogenic chemotherapy. Support Care Cancer 1998; 6:389-395
19. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006; 24:4472-4478
20. Glaus A, Knipping C, Morant R, Böhme C, Lebert B, Beldermann F, et al. Chemotherapy-Induced nausea and vomiting in routine practice: A European perspective. Support Care Cancer 2004; 12:708-715
21. Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, et al. The impact of chemotherapy-Induced nausea and vomiting on health-related quality of life. Support Care Cancer 2007; 15:179-185
22. Navari RM. Treatment of chemotherapy-Induced nausea. Community Oncol 2012; 9:20-26
23. Mulders M, Vingerhoets A, Breed W. The impact of cancer and chemotherapy: Perceptual similarities and differences between cancer patients, nurses and physicians. Eur J Oncol Nurs 2008; 12:97-102
24. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, et al. Incidence of chemotherapy-Induced nausea and emesis after modern antiemetics. Cancer 2004; 100:2261-2268
25. Di Maio M, Perrone F. Registrative trials of antiemetic drugs: Arrival or starting point? Lancet Oncol 2009; 10:533-534
26. O'Kane A. Evaluate the effects of implementing the Multinational Association of Supportive Care in Cancer (MASCC) antiemetic guideline on the incidence of chemotherapy-Induced nausea and vomiting (CINV) following platinum chemotherapy. Proc MASCC 2009. Support Care Cancer 2009; 17:857-1039
27. Aapro M, Molassiotis A, Dicato M, Pelá ez I, Rodri'guez-Lescure A, Pastorelli D, et al. on behalf of the PEER investigators. The effect of guidelineconsistent antiemetic therapy on chemotherapy-Induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER). Ann Oncol 2012; 23:1986-1992
28. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29:4189-4198
29. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- And radiotherapy-Induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol 2010; 21 (SUPPL5): V232-v243
30. Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, et al. National Comprehensive Cancer Network (NCCN). Antiemesis NCCN Guidelines 2012, version 1; 2012. Available at: Http://www.nccn.org/professionals/ physician-gls/PDF/antiemesis.pdf [Accessed 28 March 2012
31. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006; 24:2932-2947
32. Kris MG, Tonato M, Bria E, Ballatori E, Espersen B, Herrstedt J, et al. Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 2011; 19 (SUPPL1):S25-S32
33. Herrstedt J, Rapoport B,Warr D, Roila F, Bria E, Rittenberg C, et al. Acute emesis: Moderately emetogenic chemotherapy. Support Care Cancer 2011; 19 (SUPPL1):S15-S23
34. Roila F, Warr D, Aapro M, Clark-Snow RA, Einhorn L, Gralla RJ, et al. Delayed emesis: Moderately emetogenic chemotherapy (single-Day chemotherapy regimens only). Support Care Cancer 2011; 19 (SUPPL1): S57-S62
35. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-Dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10:115-124
36. Fojo T, Grady C. How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009; 101: 1044-1048
37. Grunberg SM. Cost-effective use of antiemetics. Oncology (Williston Park) 1998; 12 (SUPPL4):38-42
38. Kufe DW, Pollock RE,Weichselbaum RR, Bast RC, Gansler TS, Holland JF, et al. Pharmacoeconomics, quality of life, and antiemetics. Holland-Frei Cancer Medicine. 6th ed. Hamilton, ON: BC Decker; 2003
39. Ballatori E, Roila F, Ruggeri B, Porrozzi S, Iannopollo M, Soru G, et al. The cost of chemotherapy-Induced nausea and vomiting in Italy. Support Care Cancer 2007; 15:31-38
40. Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K, Peschel C, Eichler HG, et al. The impact of delayed chemotherapy-Induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 2004; 15:526-536
41. Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-Induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 2011; 19:131-140
42. Tina Shih YC, Xu Y, Elting LS. Costs of uncontrolled chemotherapy-Induced nausea and vomiting among working-Age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 2007; 110:678-685
43. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-Induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-Dose cisplatin - The Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21:4112-4119
44. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-Induced nausea and vomiting: Results from a randomized, double-blind, placebocontrolled trial in Latin America. Cancer 2003; 97:3090-3098
45. Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, et al. Comparison of an aprepitant regimen with a multiple-Day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-Dose cisplatin treatment. Ann Oncol 2006; 17:1000-1006
46. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapyinduced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23:2822-2830
47. Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, et al. Aprepitant for the prevention of chemotherapy-Induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support Care Cancer 2010; 18:423-431
48. Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, et al. Singledose fosaprepitant for the prevention of chemotherapy-Induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol-EASE. J Clin Oncol 2011; 29:1495-1501
49. Grunberg SM,Warr D, Gralla RJ, Rapoport BL, Hesketh PJ, Jordan K, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art. Support Care Cancer 2011; 19 (SUPPL1): S43-S47
50. Roila F, Caserta C, Fatigoni S. Antiemetic treatment. In: Maiello E, Torri V, editors. Italian Association of Medical Oncology. Guidelines 2012. Milan, Italy; 2012. pp. 1267-1286
51. Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: Trends over time in controlling chemotherapy induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage 2000; 20:113-121
52. YeoW, Mo FK, Suen JJ, Ho WM, Chan SL, LauW, et al A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-Induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 2009; 113:529-535
53. Arpornwirat W, Albert I, Hansen VL, Levin J, Bandekar RR, Grunberg SM. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-Induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer 2009; 115: 5807-5816
54. Herrstedt J, Apornwirat W, Shaharyar A, Aziz Z, Roila F, Van Belle S, et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 2009; 27:5363-5369
55. Maione P, Rossi A, Sacco PC, Bareschino MA, Schettino C, Gridelli C, et al. Advances in chemotherapy in advanced non-small-cell lung cancer. Expert Opin Pharmacother 2010; 11:2997-3007
56. Caponi S, Vasile E, Ginocchi L, Tibaldi C, Borghi F, D'Incecco A, et al. Second-line treatment for non-small-cell lung cancer: One size does not fit all. Clin Lung Cancer 2010; 11:320-327
57. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer. J Natl Cancer Inst 1999; 91:66-72
58. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95:362-372
59. Kim YH, Mishima M. Second-line chemotherapy for small-cell lung cancer (SCLC). Cancer Treat Rev 2011; 37:143-150
60. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (SUPPL8):S4-S66
61. Du Bois A, Pfisterer J. Future options for first-line therapy of advanced ovarian cancer. Int J Gynecol Cancer 2005; 15 (SUPPL1):42-50
62. Bender CM, McDaniel RW, Murphy-Ende K, Pickett M, Rittenberg CN, Rogers MP, et al. Chemotherapy-Induced nausea and vomiting. Clin J Oncol Nurs 2002; 6:94-102
63. Carey MP, Burish TG. Etiology and treatment of the psychological side effects associated with cancer chemotherapy: A critical review and discussion. Psychol Bull 1988; 104:307-325
64. Harris JG. Nausea, vomiting and cancer treatment. CA Cancer J Clin 1978; 28:194-201
65. Morrow GR. Behavioural factors influencing the development and expression of chemotherapy induced side effects. Br J Cancer SUPPL1992; 19:S54-S60, discussion S60-S63
66. Sun CC, Bodurka DC, Donato ML, Rubenstein EB, Borden CL, Basen-Engquist K, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: Do they change over timëGynecol Oncol 2002; 87:118-128
67. Borjeson S, Hursti TJ, Tishelman C, Peterson C, Steineck G. Treatment of nausea and emesis during cancer chemotherapy. Discrepancies between antiemetic effect and well-being. J Pain Symptom Manage 2002; 24:345-358
68. Hesketh PJ, Sanz-Altamira P, Bushey J, Hesketh AM. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer 2011; 20:1043-1047
69. Hesketh PJ, Bosnjak SM, Nikolic V, Rapoport B. Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecanbased chemotherapy. Support Care Cancer 2011; 19:2063-2066
70. Hesketh PJ,Wright O, Rosati G, Russo M, Levin J, Lane S, et al. Single-Dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-Induced nausea and vomiting: A multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer 2012; 20:1471-1478